PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Metsä Board Oyj (METSA.HE)
5.560.02 (-0.36%)
5.56 - 5.56
4.95 - 8.28
45 / 2.4K (Avg.)
-278.00 | -0.02
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
11.77%
Revenue growth 1.25-1.5x STERV.HE's 9.15%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
7.65%
Gross profit growth above 1.5x STERV.HE's 4.86%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
-0.91%
Negative EBIT growth while STERV.HE is at 1.27%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-0.91%
Negative operating income growth while STERV.HE is at 1.27%. Joel Greenblatt would press for urgent turnaround measures.
-3.88%
Negative net income growth while STERV.HE stands at 4.84%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-3.23%
Negative EPS growth while STERV.HE is at 2.70%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-3.23%
Negative diluted EPS growth while STERV.HE is at 2.70%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.24%
Share reduction while STERV.HE is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.68%
Reduced diluted shares while STERV.HE is at 0.01%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-97.08%
Negative OCF growth while STERV.HE is at 0.63%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-429.73%
Negative FCF growth while STERV.HE is at 18.31%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
14.89%
10Y revenue/share CAGR above 1.5x STERV.HE's 9.06%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
50.41%
5Y revenue/share CAGR above 1.5x STERV.HE's 20.81%. David Dodd would look for consistent product or market expansions fueling outperformance.
39.55%
3Y revenue/share CAGR above 1.5x STERV.HE's 17.10%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
107.78%
10Y OCF/share CAGR above 1.5x STERV.HE's 57.66%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
-92.02%
Negative 5Y OCF/share CAGR while STERV.HE is at 13.43%. Joel Greenblatt would question the firm’s operational model or cost structure.
-91.00%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-29.93%
Negative 10Y net income/share CAGR while STERV.HE is at 366.15%. Joel Greenblatt sees a major red flag in long-term profit erosion.
233.33%
5Y net income/share CAGR above 1.5x STERV.HE's 107.53%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
200.00%
Below 50% of STERV.HE's 413.56%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
99.92%
10Y equity/share CAGR in line with STERV.HE's 104.09%. Walter Schloss might see both benefiting from stable profitability and moderate payout ratios over the decade.
75.89%
5Y equity/share CAGR at 50-75% of STERV.HE's 102.23%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
39.83%
3Y equity/share CAGR at 50-75% of STERV.HE's 68.88%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
155.52%
Stable or rising mid-term dividends while STERV.HE is cutting. John Neff sees an edge in consistent payouts vs. the competitor.
56.16%
3Y dividend/share CAGR of 56.16% while STERV.HE is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
-100.00%
Firm’s AR is declining while STERV.HE shows 6.67%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
8.25%
Inventory growth well above STERV.HE's 6.18%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-3.18%
Negative asset growth while STERV.HE invests at 4.10%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
2.95%
50-75% of STERV.HE's 5.77%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
-1.37%
We’re deleveraging while STERV.HE stands at 5.82%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
10.20%
SG&A declining or stable vs. STERV.HE's 21.63%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.